Idarubicin Clinical Trials
16 recruitingDrug
Phase 212Phase 16Phase 32Not Applicable1
Showing 1–16 of 16 trials
Recruiting
Phase 1
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Acute Myeloid LeukemiaAcute LeukemiaAML+9 more
Kura Oncology, Inc.171 enrolled45 locationsNCT06001788
Recruiting
Phase 2
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
High Risk Myelodysplastic SyndromeMyelodysplastic Syndrome With Excess Blastsde Novo Myelodysplastic Syndrome+7 more
M.D. Anderson Cancer Center270 enrolled1 locationNCT00801489
Recruiting
Phase 1
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
Recurrent Chronic Myelomonocytic LeukemiaRecurrent Myelodysplastic SyndromeRefractory Chronic Myelomonocytic Leukemia+6 more
Fred Hutchinson Cancer Center120 enrolled1 locationNCT04375631
Recruiting
Phase 1Phase 2
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
High Risk Myelodysplastic SyndromeRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center116 enrolled1 locationNCT03214562
Recruiting
Phase 1
Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms
Acute Myeloid LeukemiaMyelodysplastic SyndromeMyeloproliferative Neoplasm+2 more
Fred Hutchinson Cancer Center30 enrolled1 locationNCT06034470
Recruiting
Phase 2
Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer
Acute Myeloid LeukemiaMyelodysplastic SyndromeChronic Myelomonocytic Leukemia+1 more
Fred Hutchinson Cancer Center20 enrolled1 locationNCT07046078
Recruiting
Phase 2
Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia
Acute Myeloid LeukemiaMyelodysplastic Syndrome
OHSU Knight Cancer Institute102 enrolled1 locationNCT07228273
Recruiting
Phase 1Phase 2
Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Acute Myeloid LeukemiaHigh Risk Myelodysplastic SyndromeRecurrent Acute Myeloid Leukemia+5 more
M.D. Anderson Cancer Center80 enrolled1 locationNCT04047641
Recruiting
Phase 2
Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers
Acute Myeloid LeukemiaMyeloproliferative NeoplasmBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive+4 more
M.D. Anderson Cancer Center100 enrolled1 locationNCT03589729
Recruiting
Phase 2
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
Acute Myeloid Leukemia
Massachusetts General Hospital172 enrolled9 locationsNCT04801797
Recruiting
Phase 2
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
Acute Myeloid LeukemiaMyelodysplastic SyndromeBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive+11 more
M.D. Anderson Cancer Center508 enrolled1 locationNCT02115295
Recruiting
Phase 1Phase 2
Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
Acute Myeloid LeukemiaRecurrent Chronic Myelomonocytic LeukemiaRecurrent Myelodysplastic Syndrome+11 more
Fred Hutchinson Cancer Center36 enrolled1 locationNCT06928662
Recruiting
Not Applicable
MRD-positive AML Clinical Study
AML, Adult
Institute of Hematology & Blood Diseases Hospital, China120 enrolled1 locationNCT07131059
Recruiting
Phase 2
HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML
AML
Institute of Hematology & Blood Diseases Hospital, China60 enrolled1 locationNCT06744556
Recruiting
Phase 2Phase 3
Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR
Acute Myeloid Leukemia (AML)
University Hospital, Angers3,100 enrolled56 locationsNCT02416388
Recruiting
Phase 2Phase 3
Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children
Pediatric AMLLeukemia, Monocytic, Acute
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University43 enrolled9 locationsNCT05313958